Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 10
- Registration Number
- NCT03632213
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Losartan/Amlodipine on Hemodynamics Parameters and Arterial Stiffness in Arterial Hypertension
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2018-08-17
- Target Recruit Count
- 28
- Registration Number
- NCT03626259
- Locations
- 🇲🇽
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT03563248
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2018-05-16
- Target Recruit Count
- 40
- Registration Number
- NCT03526042
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Bariatric Surgery and Pharmacokinetics of Losartan
- Conditions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03519893
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Losartan for the Treatment of Pediatric NAFLD
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-10-21
- Target Recruit Count
- 83
- Registration Number
- NCT03467217
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern Univ-Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸University of Washington, Seattle, Washington, United States
A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 66
- Registration Number
- NCT03459911
- Locations
- 🇮🇳
Clinical Unit, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India
N-of-1 Trials In Children With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2022-09-09
- Target Recruit Count
- 49
- Registration Number
- NCT03461003
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT03435939
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
The Effect of Losartan on Emotional Processing in Healthy Volunteers
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 30
- Registration Number
- NCT03434054
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.